Aligos Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated State ments of Cash Flows
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(87,679) | $(96,046) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Accretion of discount on investments | (424) | (159) |
| Amortization of right of use assets | 1,510 | 1,369 |
| Impairment of right of use assets | 724 | - |
| Change in fair value of warrant liability | 2,169 | - |
| Loss on disposal of assets | 17 | - |
| Depreciation expense | 1,559 | 2,306 |
| Stock-based compensation including ESPP | 12,652 | 14,693 |
| Changes in operating assets and liabilities: | ||
| Other assets | 2,297 | 5,594 |
| Right of use assets | - | (278) |
| Accounts payable | (2,219) | 1,722 |
| Accrued liabilities | 918 | (9,140) |
| Operating lease liabilities | (2,432) | (1,819) |
| Other liabilities | 46 | (133) |
| Deferred revenue from collaborations | (8,659) | 2,502 |
| Deferred revenue from customers | 524 | - |
| Net cash and cash equivalents used in operating activities | (78,997) | (79,389) |
| Cash flows from investing activities: | ||
| Activities in available-for-sale investments: | ||
| Maturities of short-term investments | 45,011 | 78,915 |
| Purchase of short-term investments | (11) | (104,265) |
| Purchases of property and equipment | (19) | (943) |
| Net cash and cash equivalents provided by (used in) investing activities | 44,981 | (26,293) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in connection with PIPE Offering, net of costs | 17,443 | - |
| Proceeds from issuance of pre-funded warrants in connection with PIPE Offering, net of costs | 44,980 | - |
| Proceeds from issuance of common warrants in connection with PIPE Offering, net of costs | 25,427 | - |
| Payments on finance lease | (96) | (61) |
| Proceeds from the ESPP purchase | 551 | 205 |
| Proceeds from the exercise of common stock option | 23 | 20 |
| Net cash and cash equivalents provided by financing activities | 88,328 | 164 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 54,312 | (105,518) |
| Cash, cash equivalents, and restricted cash, beginning of period | 81,462 | 186,980 |
| Cash, cash equivalents, and restricted cash, end of period | $135,774 | $81,462 |
Consolidated Statements of Cash Flows (Continued)
(In thousands)
| Twelve Months Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Reconciliation to amounts on the Consolidated Balance Sheets: | ||||
| Cash and cash equivalents | $135,704 | $81,347 | ||
| Restricted cash | 70 | 115 | ||
| Total cash, cash equivalents, and restricted cash | $135,774 | $81,462 | ||
| Supplemental disclosures of noncash financing and investing activities: | ||||
| Receivable due from arrangement | $ | - | $700 | |
| Mark to market adjustment for available-for-sale investments | $96 | $(57) | ||
| Acquisition of right of use asset through operating lease obligation | $1,094 | $ | - | |
| Vesting of early exercised options | $66 | $209 | ||
| Change in pension obligation | $48 | $6 | ||
Aligos Therapeutics, Inc.
Notes to consolidated
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.